BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Wall Street ends mixed as investors focus on tech earnings
Cowen Starts Regulus Therapeutics (RGLS) at Outperform
October 31, 2012 8:27 AM EDTCowen initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday, with a 52 week range of $4.02-$5.48.... More
